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Growth and differentiation of thymocytes and T lymphocytes is in part
regulated by soluble factors that are released by lymphocytes themselves or by
nonlymphoid cells in the thymus, lymph nodes, or at sites of inflammation (1, 2) .
B cell stimulating factor (BSF-2), which is now known to be identical to IFN-R2,
hybridoma plasmacytoma growth factor (HPGF), or 26-kD protein and recently
named IL-6, was initially thought to be a lymphokine ofT cell origin whose
major role was in the induction of differentiation of activated B lymphocytes
into antibody-secreting cells (reviewed in references 3, 4) . Recently, however,
multiple nonlymphoid cells have been found to be capable of either producing
this cytokine or of responding to it . Thus, monocytes (5), fibroblasts (6, 7),
hepatocytes (Lotz, M., B. Zuraw, F . Jirik, and D. A. Carson, submitted for
publication), cardiac myxoma (8), glial (9), and vascular endothelial cells (Jirik,
F. R., T. J . Podor,T. Hirano, T. Kishimoto, D. J . Loskutoff, D. A . Carson, and
M . Lotz, submitted for publication) all appear capable of IL-6 production . In
addition to the effects on B lymphocytes, IL-6 has other important functions,
such as the regulation of fibroblast proliferation (6, 7) and acute phase protein
production by hepatocytes (9, 10, 11). This broad spectrum of IL-6 sources and
actions has significantly altered the character of IL-6 from that of a T cell-
derived lymphokine acting on B cells, to that of a pleiotropic mediator that is
similar to IL-1 in the diversity of its effects on cell function . The findings
reported here support this notion and document a role for IL-6 in T cell
activation .
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Materials and Methods
BriefDefinitive Report
Thymocyte Isolation . Human thymocytes were isolated from glands obtained from
pediatric patients (3 mo to 2 yr old) undergoing corrective cardiac surgery . The tissue
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FIGURE 1 . BSF-2/IL-6 augments pro-
liferation of PHA-activated human thy-
mocytes . Cells were stimulated with the
indicated combinations of BSF-2/IL-6
and PHA (0.5%) . Proliferation wasmeas-
ured after 4 d . Data are shown as cpm±
SEM.
was finely minced and single cell suspensions were fractionated over Ficoll-Hypaque
gradients. Cells isolated by this technique usually were 99% positive for the CD2 antigen,
as analyzed by flow cytometry.
Thymocyte Cultures.
￿
Cells were resuspended in RPMI 1640, supplemented with 2%
heat-inactivated FCS, 2MM L-glutamine, 50 AM 2-ME and antibiotics . 1-2 x 10 5 cells in
200 AI medium were added per well in 96-well flat-bottomed plates . During the last 4 h
of the 96-h culture, [sH]thymidine (sp act 60 Ci/mmol, 1 PCi/well) was added. The cells
were harvested by filtration and radioactivitywas counted by scintillation spectrophotom-
etry . Peripheral bloodT lymphocytes were purified as described previously (12) .
Reagents. Antibody to the IL-2-R was purchased from Becton Dickinson & Co .,
Mountain View,CA . This antibody inhibits thebinding of IL-2 and hassimilar reactivity
as anti-Tac . Human rIL-2 was kindly provided by Cetus Corp ., Palo Alto, CA .
Results
Initially we found that human rBSF-2/IL-6 had growth-promoting activity on
PHA-activated thymocytes from (C3H/Hej) mice, which are commonly used in
the lymphocyte-activating factor assay to detect IL-1 activity . Subsequently we
prepared human thymocytes (?99% CD2+) from normal thymus to determine
whether they also responded to BSF-2/IL-6 . rBSF-2/IL-6 increased proliferation
of these cells approximately sevenfold above the response induced by PHA (0.2-
0.5% wt/vol) alone . This effect was dose dependent and low doses ofBSF-2/IL-
6 between 0.1 and 1 U/ml still gave significant stimulation (Fig. 1) . In all of the
thymocyte preparations tested, BSF-2/IL-6 consistently stimulated proliferation
significantly . The magnitude of the BSF-2/IL-6 effect showed some variability,
which may reflect the contamination of thymocytes with a low proportion (<1%)
of adherent cells that are capable of producing BSF-2/IL-6 (Lotz, M ., et al .,
unpublished observations) . The addition of BSF-2/IL-6 alone in the absence of
PHA did not result in a detectable increase in proliferation (not shown) .
The effects ofBSF-2/IL-6 on mature T lymphocytes isolated from peripheral
blood were then examined . In an initial series of experiments, unfractionated
PBMC were stimulated with a broad range ofPHA (0.001-1%) concentrations .
Under these conditions, even the use of high doses of BSF-2/IL-6 resulted in
only minor, nonsignificant increases in proliferation . However, if the PBMC
populations were depleted ofmonocytes (<_0.5% esterase-positive) by the use ofLOTZ ET AL.
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FIGURE 2. BSF-2/IL-6 effect on
proliferation of purified T lympho-
cytes from peripheral blood. T lym-
phocytes that were essentially free of
monocytes were cultured for 3 d in
the presence of PHA (0.5%) and the
indicated doses of BSF-2/IL-6. Pro-
liferation was assayed by ['Hlthymi-
dine incorporation. Data are shown
as cpm t SEM.
E-rosetting and carbonyl-iron treatment (12), a response to exogenous BSF-2/
IL-6 was evident. Similar to the results obtained with thymocytes, at suboptimal
doses of PHA (0.1-0.5%), BSF-2/IL-6 gave a dose-dependent increase in prolif-
eration (Fig. 2).
The following series ofexperiments examined whether the proliferative action
ofBSF-2/IL-6 on thymocytes and T lymphocytes was mediated via the IL-2/IL-
2-R pathway. To test for BSF-2/IL-6 effects on IL-2-R expression, thymocytes
were cultured for 48 h in medium alone, PHA (0.5%) alone, or in the presence
of both PHA and BSF-2/IL-6 (100 U/ml). The cells were stained with directly
fluoresceinated antibody to the IL-2-R (P55 component) and analyzed by flow
cytometry (13). The relative proportions of cells expressing IL-2-R were 3.6%
in the control medium, 28.2% in the PHA-stimulated cells, and 33.8% in the
presence ofPHA and BSF-2/IL-6 . Similar results were obtained using monocyte-
depleted PBMC where the relative numbers were 4.2%, 19.6%, 19%, respec-
tively. Cultures prepared in parallel, using identical cell populations, and supple-
mented with PHA and BSF-2/IL-6, showed the expected augmentation of cell
proliferation. These results suggested that the BSF-2/IL-6 stimulation ofT cells
was not associated with an increase in IL-2-R expression. A separate approach
was then used to strengthen this observation. Thymocytes were stimulated with
PHA, or with combinations of PHA and IL-2 or BSF-2/IL-6. mAb to the IL-2-
R was added to these cultures and proliferation was measured after 72 h. Table
I shows that antibody to the IL-2-R at 1 ug/ml markedly inhibited the response
of the cells to the combination of PHA and IL-2, whereas the proliferative
response to PHA and BSF-2/IL-6 was not significantly depressed. At higher
doses ofantibody (10 tcg/ml), which reduced the response to PHA alone, the IL-
2 effect and also most of the IL-6 effect were inhibited. Leu-12 (an anti-B cell
mAb ofthe same subclass [IgGl] as the anti-IL-2-R antibody) used as control, did
not interfere with the proliferative effect of either cytokine. Together, these
observations indicate that the effect of BSF-2/IL-6 on T cell proliferation is
probably not exclusively dependent on the IL-2/IL-2-R pathway.1256
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TABLE I
Mechanism ofBSF-2/IL-6-induced TCell Proliferation
Human thymocytes and purified blood T lymphocytes (PBT) were stimulated with PHA (0.5%
wt/vol) and IL-2 (10 U/ml) or BSF-2/IL-6 (10 U/ml). PHA-activated cells were preincubated for 2
hat37°C with antibody to IL-2-11or with Leu-12. ['H]Thymidine incorporation was measured after
4 d in culture. Data are shown as cpm, and are the mean of triplicate cultures. Variation between
sampleswas<<-10%.
Discussion
These experiments have identified BSF-2/IL-6 as a novel costimulant for
human thymocytes and mature T lymphocytes. IL-6 has comitogenic activity for
T lymphocytespreactivated withsuboptimaldosesofPHA, but does not stimulate
proliferation oflymphocytes in theabsenceofmitogen. This dependence ofBSF-
2/IL-6 on mitogen prestimulation is consistent with the two-signal requirement
for T cell activation. IL-6 effects on T lymphocytes isolated from peripheral
blood were only detectable after monocyte depletion, as these cells are capable
of producing IL-6 (3). BSF-2/IL-6-mediated increases in proliferation do not
appear to be mediated via increases in IL-2-R expression. In addition, doses of
antibody to the IL-2-R that inhibited proliferation induced by exogenous IL-2
did not significantly affect the response to BSF-2/IL-6 response. At higher doses
of antibody the IL-6 effects were significantly inhibited, although to a lesser
degree than IL-2 effects. These results suggest that the IL-6 effect is not
exclusively dependent on the IL-2/IL-2-Rpathway. The observed effects ofBSF-
2/IL-6 on T lymphocytes are consistent with the expression of BSF-2/IL-6
receptors on these cells (14) and indicate that this cytokine can potentiate not
only humoral but also cellular immune responses.
Summary
Growth and differentiation of thymocytes and mature Tlymphocytes is regu-
lated by cellular interactions that are in part mediated by soluble factors. We
identify IL-6, formerly called B cell stimulating factor (BSF-2), IFN-,82, or
hybridoma-plasmacytoma growth factor (HPGF) as a novel T cell costimulant.
rIL-6 induced a six- to seven-fold increase in proliferation of human thymocytes
stimulated with suboptimal doses of PHA. A similar effect with added IL-6 could
Antibody
PHA
Thymocytes
PHA
IL-2
PHA
IL-6 PHA
PBT
PHA
IL-2
PHA
IL-6
No anti- 1,872 19,349 10,420 7,538 42,811 31,682
body
Anti-IL-2-R 1,022 4,418 8,937 5,132 9,246 28,443
(1 kg/ml)
Anti-IL-2-R 376 836 2,131 792 1,233 2,942
(10
hg/ml)
Leu-12 1,632 20,318 11,987 6,044 40,206 30,491
(1 jug/ml)
Leu-12 1,327 18,599 9,983 7,639 43,932 29,935
(10
jig/ml)LOTZ ET AL.
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be observed using peripheral blood T lymphocytes, but only if the cultures were
first rigorously depleted of monocytes that release high levels of IL-6. Analysis
of the mechanism of the IL-6 effect on thymocytes and T lymphocytes showed
that IL-6 did not lead to an increase in IL-2-R expression . Concentrations of
antibody to IL-2-11 inhibiting IL-2 effects did not block the IL-6-induced prolif-
eration, indicating that the IL-6 effect was relatively IL-2 independent. These
results identify IL-6 as a novel costimulant of human thymocytes and mature T
lymphocytes, and suggest that IL-6 is also an important regulatory of cellular
immunity.
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Note added in proof: After submission of this manuscript similar results on murine cells were
reported (15).
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